TS
VRNA

Thomas Steyer’s Verona Pharma VRNA Stock Holding History

Thomas Steyer’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,810,000
Closed -$171M – 164
2025
Q2 		$171M Buy
1,810,000
+725,011
+67% +$53.7M 0.72% 38
2025
Q1 		$68.9M Buy
+1,084,989
New +$64.9M 0.33% 50

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Thomas Steyer's VRNA Position: Q3 2025 in Review

Thomas Steyer sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 1,810,000 shares — an estimated $171M sold.

Thomas Steyer first reported a position in VRNA in Q1 2025 and held it in 2 quarters. The position peaked at $171M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Thomas Steyer reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Thomas Steyer sold 1,810,000 Verona Pharma shares in Q3 2025, an estimated $171M.
  • Thomas Steyer first reported a position in Verona Pharma in Q1 2025 and held it in 2 quarters.
  • Thomas Steyer's Verona Pharma position peaked at $171M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.